Atea Pharmaceuticals (AVIR) Research & Development (2020 - 2022)
Historic Research & Development for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $27.5 million.
- Atea Pharmaceuticals' Research & Development fell 5236.2% to $27.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $81.9 million, marking a year-over-year decrease of 5099.64%. This contributed to the annual value of $144.1 million for FY2024, which is 2613.55% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Research & Development stood at $27.5 million for Q4 2022, which was down 5236.2% from $4.9 million recorded in Q3 2022.
- Atea Pharmaceuticals' 5-year Research & Development high stood at $57.8 million for Q4 2021, and its period low was $4.9 million during Q3 2022.
- Over the past 3 years, Atea Pharmaceuticals' median Research & Development value was $26.6 million (recorded in 2021), while the average stood at $25.8 million.
- As far as peak fluctuations go, Atea Pharmaceuticals' Research & Development surged by 41325.6% in 2021, and later tumbled by 8859.81% in 2022.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' Research & Development stood at $13.8 million in 2020, then surged by 317.53% to $57.8 million in 2021, then plummeted by 52.36% to $27.5 million in 2022.
- Its Research & Development was $27.5 million in Q4 2022, compared to $4.9 million in Q3 2022 and $19.9 million in Q2 2022.